Topical application of platelet-rich fibrin in the management of chemoradiotherapy-induced oral mucositis: a retrospective analysis of clinical outcomes

Background: Oral mucositis (OM) is a prevalent and debilitating complication arising from chemoradiotherapy in oncologic patients, characterized by painful ulcerations that significantly impair oral functions and quality of life. Platelet-rich fibrin (PRF), an autologous biomaterial rich in growth factors and cytokines, has shown promise in enhancing tissue regeneration and wound healing.​ Objective: This retrospective study aims to evaluate topical PRF application’s clinical efficacy and safety in treating OM among patients undergoing chemotherapy and/or radiotherapy.​ Methods: A total of 15 patients diagnosed with grade II–III OM were included in this analysis. PRF gel was prepared from autologous blood and applied topically to the mucosal lesions biweekly. Clinical outcomes were assessed based on lesion size reduction, pain relief (measured using a Visual Analog Scale), reepithelialization, and the occurrence of any adverse effects over a follow-up period of six months. Results: The application of PRF resulted in a significant reduction in lesion size and pain levels, with complete reepithelialization observed after a median of three applications (range: 2–8). Two patients reported transient mild discomfort at the application site, which resolved spontaneously. One patient experienced a recurrence of OM at five months post-treatment. No severe adverse effects or secondary infections were noted.​Conclusion: Topical PRF application is a safe and effective adjunctive therapy for managing OM in chemoradiotherapy patients, promoting accelerated healing and symptomatic relief.​